Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1622 1625 1654
This examiner grants 42% of resolved cases
Andrew D. Kosar is an examiner in Tech Center 1600 and Art Unit 1600. He has resolved 269 cases, providing a picture of his examination tendencies. His allowance rate is 42.0 percent, suggesting a challenging prosecution environment for applicants.
The interview lift for this examiner is 31.8 percent. This positive lift indicates that an interview is a tool for moving an application toward allowance. Given the 42.0 percent baseline, the 31.8 percent lift is an incentive for practitioners to engage in direct dialogue with the examiner.
The median days to allowance is 1269, which is the typical timeframe for securing a patent under his review. This 1269-day median is a data point for applicants planning their prosecution strategy. With 269 resolved cases, the 42.0 percent allowance rate and the 31.8 percent lift are the primary metrics for evaluating success in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18842578 | PYRIMIDINLY-OXY-QUINOLINE BASED HERBICIDAL COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18034661 | THERAPEUTIC AGENT FOR COVID-19 | Non-Final OA | TOHOKU UNIVERSITY |
| 18759283 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | Non-Final OA | Gilead Sciences, Inc. |
| 18068406 | SCREENING METHOD FOR LAMININ 511 PRODUCTION PROMOTING AGENT, BASAL EPIDERMAL LAYER STABILIZING AGENT, AND/OR EPIDERMAL STEM CELLS REDUCTION INHIBITING OR PROLIFERATION PROMOTING AGENT | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18870743 | COMBINATION THERAPY FOR TREATING CANCER | Non-Final OA | AstraZeneca AB |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | Non-Final OA | Taiho Pharmaceutical Co., Ltd. |
| 18856302 | NOVEL SULFONATE BENZAMIDE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | Non-Final OA | FMC CORPORATION |
| 18497386 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | Non-Final OA | Genzyme Corporation |
| 18396017 | PURINONE DERIVATIVE HYDROCHLORIDE | Non-Final OA | ONO PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy